use of MTX
MTX conjugates
Liposomal MTX
SSZ
treatment of RA
RA models
mouse model of RA
RA mouse model
Folate-Target Nanodevices
FBN
clinical trials novel folate-based nanodevices
temperature sensitive nanodevices
drug release
improved clinical scores
line biological therapies
treatment of rheumatoid arthritis
line drug therapy
Rheumatoid Arthritis FOLSMART
HSA-FA
Pre-clinical development
line indication
best therapies bench
optimization of mechanisms
Phase
mediated targeting of activated macrophages
Good Laboratory Practice
Good Manufacturing Practice
improved tolerance
animal models
greater efficacy
efficacy benefit
intolerant patients
Specific technological objectives of FOLSMART
great economic burden
initial economic evaluation
comparison
hospital
production
significant associated toxicity
previous FP7 European project NANOFOL
public health systems
tolerability
drugs
dog
GMP
neck domain
folic acid
proposed treatments
peptide
GLP
standards
application
agent
pharmacokinetics
fields
Nanoparticles
Sulfasalazine
methotrexate
exploitation
business plans
Toxicology
way
Genotoxicity
Carcinogenicity
alternatives
claims